Spyre Therapeutics, Inc. short interest in 2022
In 2022, Spyre Therapeutics, Inc.'s disclosed short interest ran from 1.46% of shares outstanding on 14 Jan 2022 to 1.63% on 30 Dec 2022, a change of +0.17 percentage points. The year's high was 5.18% on 15 Jun 2022 and its low 0.85% on 14 Oct 2022, averaging 2.46% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.58 days on 31 May 2022. Full history: Spyre Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 1.46% (14 Jan 2022)
- End of year
- 1.63% (30 Dec 2022)
- Change
- +0.17 pp
- High
- 5.18% (15 Jun 2022)
- Low
- 0.85% (14 Oct 2022)
- Average
- 2.46%
- Highest days to cover
- 9.58 (31 May 2022)
- SEC filings marked
- 9
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 1.46% | 1.99 | |
| 31 Jan 2022 | 1.74% | 3.81 | |
| 15 Feb 2022 | 3.21% | 5.80 | results (8-K) |
| 28 Feb 2022 | 2.86% | 7.56 | |
| 15 Mar 2022 | 2.83% | 3.14 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 4.10% | 6.47 | |
| 14 Apr 2022 | 4.38% | 1.26 | |
| 29 Apr 2022 | 4.54% | 6.98 | |
| 13 May 2022 | 4.34% | 3.20 | 10-Q filed, results (8-K) |
| 31 May 2022 | 4.02% | 9.58 | |
| 15 Jun 2022 | 5.18% | 1.45 | |
| 29 Jul 2022 | 1.65% | 5.04 | |
| 15 Aug 2022 | 1.91% | 1.83 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 1.32% | 1.00 | |
| 15 Sep 2022 | 1.05% | 1.45 | |
| 30 Sep 2022 | 1.12% | 2.95 | |
| 14 Oct 2022 | 0.85% | 1.90 | |
| 31 Oct 2022 | 0.99% | 1.00 | |
| 15 Nov 2022 | 1.92% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 1.33% | 1.00 | |
| 15 Dec 2022 | 1.65% | 1.00 | |
| 30 Dec 2022 | 1.63% | 2.25 |
See also: Spyre Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.